Larimar Therapeutics Inc expected to post a loss of 48 cents a share - Earnings Preview

Larimar Therapeutics

01/08/2025 14:32

Larimar Therapeutics Inc LRMR.OQ LRMR.O is expected to  show no change in quarterly revenue when it reports  results on August 5 (estimated) for the period ending June 30 2025

​LSEG's mean analyst estimate for Larimar Therapeutics Inc is for a loss of 48 cents per share.

The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 12 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."

The mean earnings estimate of analysts was unchanged in the last three months. ​

Wall Street's median 12-month price target for Larimar Therapeutics Inc is $18.00, about 80.8% above its last closing price of $3.46

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Mar. 31 2025
-0.42
-0.42
-0.46
Missed
-10
Dec. 31 2025
-0.34
-0.32
-0.45
Missed
-41.9
Sep. 30 2024
-0.39
-0.37
-0.24
Beat
36​
Jun. 30 2024
-0.32
-0.31
-0.34
Missed
-11.4
​​Mar. 31 2024
-0.23
-0.23
-0.27
Missed
-14.9
Dec. 31 2023
-0.26
-0.25
-0.30
Missed
-21.3​
Sep. 30 2023
-0.21
-0.22
-0.21
Beat
6
Jun. 30 2023
-0.18
-0.19
-0.19
Met
2.6

This summary was machine generated August 1 at 13:32 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)